Clinically-Related 483's and Warning Letters: Getting through the Maze

(complianceonline.com)

This webinar on Clinically-Related 483's and Warning Letters will show how you can manage clinical site FDA inspections, handle issues, understand and respond to observations ("483") and/or Warning Letters.

Why Should You Attend:

FDA inspections of clinical trial sites, sponsors and IRBs have yielded observations (reported on FDA Form 483, or “483’s) and Warning Letters.

NOTE : Use this Promocode (128600) to avail 10% discount, valid upto 6th December 2011.